Stockscreener 앱 받기
106.47
0.60%
0.63
시간 외 거래:
106.47
전일 마감가:
$105.84
열려 있는:
$106.68
하루 거래량:
6.35M
Relative Volume:
0.88
시가총액:
$157.52B
수익:
$18.49B
순이익/손실:
$2.51B
주가수익비율:
63.38
EPS:
1.68
순현금흐름:
$2.72B
1주 성능:
+3.21%
1개월 성능:
-0.06%
6개월 성능:
+3.66%
1년 성능:
+40.85%
1일 변동 폭
$106.10
$107.25
1주일 범위
$104.69
$108.53
52주 변동 폭
$71.88
$108.53
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
106.47 | 156.58B | 18.49B | 2.51B | 2.72B | 1.68 |
|
ABT
Abbott Laboratories
|
128.01 | 219.83B | 43.11B | 13.98B | 6.66B | 7.98 |
|
SYK
Stryker Corp
|
400.57 | 153.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.44 | 117.84B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.47 | 46.04B | 5.69B | 4.15B | 623.10M | 6.95 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
Boston Scientific Corporation Reversal Rally May Surprise BearsOversold Bounce Stock Play Ideas Gain Attention - metal.it
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott - GlobeNewswire Inc.
Boston Scientific’s SWOT analysis: innovation drives stock amid challenges - Investing.com
What are the technical indicators suggesting about Boston Scientific CorporationSuperior returns - jammulinksnews.com
RBC Capital Raises PT on Boston Scientific Corporation (BSX) to $125 From $120 - Insider Monkey
What are the latest earnings results for Boston Scientific CorporationIdentify undervalued stocks poised to rally - jammulinksnews.com
How does Boston Scientific Corporation compare to its industry peersMaximize portfolio growth with professional advice - jammulinksnews.com
Boston Scientific Corporation (BSX) Is One Of The Most Reliable Companies, Says Jim Cramer - Insider Monkey
TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX) - Insider Monkey
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
FSHPU seeks shareholder OK to cut extension fee to $60k/month, preserve GFT merger | BSX SEC FilingForm 144 - Stock Titan
Boston Scientific's (NYSE:BSX) investors will be pleased with their solid 173% return over the last five years - Yahoo.co
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - MSN
Boston Scientific Reports Strong Q2 2025 Results - The Globe and Mail
Boston Scientific (BSX) Target Price Raised by Raymond James | B - GuruFocus
Boston Scientific (BSX) Price Target Raised by Oppenheimer | BSX Stock News - GuruFocus
Boston Scientific stock price target raised to $125 from $120 at RBC Capital - Investing.com
Is Boston Scientific Corporation stock overhyped or has real potentialSuperior stock growth - jammulinksnews.com
Boston Sci posts 117% U.S. PFA growth, halves tariff impact - BioWorld MedTech
Boston Scientific stock price target raised to $130 from $124 at Bernstein - Investing.com Canada
Boston Scientific (BSX) Price Target Increased by RBC Capital | - GuruFocus
BSX: Boston Scientific Sees Price Target Raised by Truist Securi - GuruFocus
Stocks making big moves yesterday: Power Integrations, Booz Allen Hamilton, Wendy's, SentinelOne, and Boston Scientific - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Baird Analyst | B - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Call Transcript - Insider Monkey
Boston Scientific stock price target raised to $140 from $130 at Mizuho - Investing.com
Boston Scientific (BSX) Price Target Increased by Baird | BSX Stock News - GuruFocus
Boston Scientific (BSX) Price Target Raised to $118 by Oppenheimer | BSX Stock News - GuruFocus
UBS Boosts Price Target for Boston Scientific (BSX) Amid Strong Performance | BSX Stock News - GuruFocus
Boston Scientific stock price target raised to $135 by UBS on strong product cycle - Investing.com
Company News for Jul 24, 2025 - The Globe and Mail
Boston Scientific stock price target raised to $124 by Wells Fargo on PFA growth - Investing.com
Boston Scientific (BSX) Sees Price Target Boost from Barclays | - GuruFocus
Boston Scientific Corp (BSX) Q2 2025 Earnings Call Highlights: Surpassing Expectations with ... By GuruFocus - Investing.com Canada
Boston Scientific: Q2 Earnings Snapshot - Greenwich Time
Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating - TipRanks
Should You Buy or Sell Boston Scientific Stock Ahead of Its Upcoming Earnings? - Nasdaq
Why Boston Scientific (BSX) Stock Is Up Today - Yahoo Finance
Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise - Yahoo Finance
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up - The Globe and Mail
Boston Scientific stock price target raised to $120 by BofA Securities - Investing.com
Boston Scientific (BSX) Price Target Increased by BofA Analyst | - GuruFocus
Boston Scientific Presses Its Advantage in Pulsed Field Ablation - Morningstar
Boston Scientific halves expected tariff hit - MedTech Dive
Boston Scientific Lifts Outlook On Cardiovascular Revenue Growth - Finimize
Boston Scientific lifts annual profit forecast, sees smaller tariff impact - Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact By Reuters - Investing.com
Boston Scientific stock hits all-time high at 107.76 USD By Investing.com - Investing.com Nigeria
Boston Scientific stock hits all-time high at 107.76 USD - Investing.com
Earnings call transcript: Boston Scientific Q2 2025 beats expectations, stock rises - Investing.com
Boston Scientific lifts annual profit view on steady heart devices demand - Yahoo.co
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.51%
자본화:
|
볼륨(24시간):